eFFECTOR Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • eFFECTOR Therapeutics's estimated annual revenue is currently $5.3M per year.(i)
  • eFFECTOR Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • eFFECTOR Therapeutics has 34 Employees.(i)
  • eFFECTOR Therapeutics grew their employee count by 3% last year.

eFFECTOR Therapeutics's People

NameTitleEmail/Phone
1
VP, Development OperationsReveal Email/Phone
2
VP FinanceReveal Email/Phone
3
VP, Preclinical Development & Clinical PharmacologyReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Chief Business OfficerReveal Email/Phone
6
Director Development OperationsReveal Email/Phone
7
Director Development OperationsReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
AP & Payroll ManagerReveal Email/Phone
10
Senior Accounting ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is eFFECTOR Therapeutics?

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR's product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

eFFECTOR Therapeutics News

2022-04-13 - -$0.32 Earnings Per Share Expected for eFFECTOR ...

Analysts expect eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) to report earnings of ($0.32) per share for the current fiscal...

2022-04-13 - eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Receives ...

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Receives Consensus Recommendation of “Buy” from Analysts. Posted by admin on Apr 20th, 2022.

2022-03-30 - eFFECTOR Therapeutics Announces Transition in Clinical ...

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.5M346%N/A
#2
$5.7M34-8%N/A
#3
$3.9M34N/AN/A
#4
$2.6M3431%$43M
#5
$3.6M34-41%$132.5M